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ABSTRACT 
Background: In randomized controlled trials of antipsychotics, various cutoffs have been used to 
define response on continuous outcome measures. 
Aims: To find a summary effect measure that remains constant across different definitions of response 
Method: We conducted secondary analyses of individual patient data from 10 randomized controlled 
trials of second generation antipsychotics for schizophrenia (n=4278) by applying a meta-analytic 
approach to produce odds ratios (OR), risk ratios (RR) and risk differences (RD) and their 95% 
confidence intervals (CI) for different definitions of response, using cutoffs of 10% through 90% 
reduction on the symptom severity rating scales. Constancy of these indices was examined through 
visual inspection, by way of I-squared statistics to quantify heterogeneity, and by way of coefficients of 
variation. If any of these indices were found to remain reasonably constant, we next examined the 
concordance between the number needed to treat (NNT) predicted from them and the observed NNT. 
Results: OR and RR remained reasonably constant across various definitions of response, especially for 
those using thresholds of 10% through 70% reduction. The NNTs predicted from OR and RR agreed 
well with the observed NNTs, with ANOVA intraclass correlation coefficients of 0.96 (95% CI: 0.92 to 
0.98) and 0.86 (0.72 to 0.93), respectively. 
Conclusions: The relative measures of treatment effectiveness remain reasonably constant across 
different scale-derived definitions of response and, in conjunction with varying control event rates, can 
give accurate estimates of NNTs for individuals with schizophrenia. 
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1. INTRODUCTION 
In psychiatry “hard” outcomes such as death are not readily available or appropriate indices of 
treatment effectiveness. Instead, continuous outcomes based on rating scales are often employed but it 
is sometimes not easy to interpret the meaning of these scores (Norman et al., 2001). For example, in a 
hypothetical drug trial of acute phase treatment of schizophrenia, a statistically significant difference on 
a certain disease severity measure of 70 vs 80 may be reported for the drug and placebo arms, 
respectively, at the end of the trial. However, what these 70 or 80, or what this 10-point difference, on 
this scale means clinically may often not be transparent. 
On the other hand, a categorical approach can be more interpretable, for example, if the response or 
remission rates are reported to be 50% vs 30% in the two arms. Trialists have therefore often included 
“response” rates defined as a threshold decrease on the continuous outcome (Altman and Royston, 
2006). Unfortunately, for many of these continuous outcomes, there usually is no validated or even 
agreed-upon cutoff to define “response.”  In the case of schizophrenia trials, the Brief Psychiatric Rating 
Scale (BPRS) (Overall and Gorham, 1962) and the Positive and Negative Syndrome Scale (PANSS) (Kay 
et al., 1987) are the two most frequently used scales but investigators have used various percentage 
improvements from 20% through 50% to define response (Beasley et al., 1996b; Marder and Meibach, 
1994; Peuskens and Link, 1997; Small et al., 1997). 
Such lack of consensus in the definition of response poses several related difficulties. First, there is 
suspicion that the trialists choose their cutoff not because it is clinically appropriate but because it is 
more likely to result in “statistically significant” differences. In recent reports of schizophrenia trials 
there is a tendency to use 20% reduction as a cutoff, apparently in the belief that a lower cutoff 
increases the ability to find statistically significant differences between drugs. However, 20% reduction 
represents something less than “minimal improvement” (Leucht et al., 2005a; Leucht et al., 2005b). A 
statistically significant difference in the rates of patients showing borderline or greater improvement 
(but not necessarilty in moderate or greater improvement) would certainly not be clinically meaningful. 
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Second, in order to obtain unbiased and generalizable estimates of the true treatment effects, we need 
comprehensive meta-analyses of relevant trials. However, if “response” is defined variably across 
different trials addressing a similar clinical question, we cannot be sure if we could safely combine them 
in a meta-analysis.  
These problems would be greatly ameliorated if one could find a measure of effect that remained more 
or less constant across a range of thresholds. The odds ratio (OR), relative risk (RR) and risk difference 
(RD) or its inverse, number needed to treat (NNT), are the representative indices of treatment 
effectiveness for dichotomous outcomes. When the outcome is dichotomous, the results of a trial can be 
summarized  as in the following 2*2 table. 
 Response Non-response 
Treatment a b 
Control c d 
The more clinically interpretable indices are RR and RD. RR  is the ratio of the response rates in the 
treatment and control arms; it is therefore  (a/(a+b))/(c/(c+d)). RD is the difference in the response 
rates in the treatment and control arms; it is therefore a/(a+b) - c/(c+d). NNT, which is the inverse of 
RD, shows the number of patients one would need to treat in order to have one more response in the 
treatment arm that would not have happened if on the control arm. It therefore nicely summarizes the 
amount of effort that both clinicians and patients need to expend in order to obtain one more response. 
For example, a treatment that produces a response rate of 50% in comparison with a placebo response 
rate of 30% would be translated into an NNT of 1/(0.5 - 0.3) = 5. In other words, one would need to 
treat 5 patients in order to produce one more responder over what would have happened on placebo. 
On the other hand, OR is intuitively difficult to understand because it is the ratio of the odds of showing 
response over not showing response in the treatment and control arms; hence it is (a/b)/(c/d) or ad/bc. 
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OR, however, has some strong mathematical properties because OR of non-response is the inverse of 
OR of response, whereas such a relationship does not hold for RR (Deeks, 2002). 
In the following analyses, we examined individual patient data from several clinical trials of 
schizophrenia to see if any of OR, RR or RD may remain constant across different definitions of response, 




Individual patient data from 10 trials comparing olanzapine vs haloperidol (5 comparisons, baseline 
n=2974) (Beasley et al., 1997; Beasley et al., 1996b; Keefe et al., 2006; Lieberman et al., 2003; Tollefson 
et al., 1997), amisulpride vs haloperidol (4 comparisons, baseline n=1198) (Carriere et al., 2000; 
Colonna et al., 2000; Moller et al., 1997; Puech et al., 1998), and olanzapine vs placebo (2 comparisons, 
baseline n=502) (Beasley et al., 1996a; Beasley et al., 1996b) that administered either the BPRS or 
PANSS were reanalyzed post hoc. These 10 trials were selected from among the 13 trials that compared 
olanzapine and 7 trials that compared amisulpride against various other antipsychotics or placebo and 
that had been provided to us by respective manufacturers, when they compared olanzapine vs 
haloperidol, amisulpride vs haloperidol or olanzapine vs placebo because these were the only 
comparisons that resulted in statistically significant differences between the compared arms when 
meta-analyzed. Working with non-significant ORs, RRs or RDs would not reveal their differential 
performances. One trial was a three-armed trial among olanzapine, haloperidol and placebo, and 
contributed to two comparisons. Table 1 summarizes important characteristics of the included studies. 
All studies were randomized and all but one (Colonna et al., 2000) were described as double-blind. All 
amisulpride studies and one olanzapine study (Beasley et al., 1996b) used the original BPRS, and all the 
other olanzapine studies used PANSS. For the latter studies we calculated the PANSS-derived BPRS 
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scores because PANSS includes all items of the BPRS. The BPRS is a clinician-rated rating scale designed 
to measure change in psychopathology and contains 18 items, each of which is rated on a seven-point 
scale ranging between 1=”not present” and 7=”extremely severe,” resulting in a total score between 18 
and 126 (Overall and Gorham, 1962). The PANSS was developed to improve on the BPRS by including 
all its items and by adding  12 more items to cover broader psychopathology; its score therefore ranges 
between 30 and 210 (Kay et al., 1987). 
For fixed-dose studies, we selected only those arms with optimum doses of second-generation 
antipsychotic drugs as reported in dose-finding studies (amisulpride 400-800 mg/day, olanzapine 10-
20 mg/day and risperidone 4-6 mg/day) (Leucht et al., 2009). We therefore excluded 61 participants 
from Puech et al (1998) who had received a potentially subtherapeutic 100 mg/day of amisulpride, 175 
participants from Beasley et al (1997) who received 5 mg/day or 1 mg/day of olanzapine, 65 
participants from Beasley et al (1996b) who were given 5 mg/day of olanzapine and 52 participants 
from Beasley et al (1996a) who received 1 mg/day of olanzapine. The active comparator, haloperidol, 
was given in a fixed dose of 15 mg/day or 16 mg/day or in variable dosage ranging between 2 and 30 
mg/day: these dosages have been found to show similar effectiveness (Leucht et al., 2009; Waraich et al., 
2002). 
The mean BPRS total score of the included participants was 54.3 (SD=10.8) at baseline, which would 
correspond with “markedly ill” range (Leucht et al., 2005a). There were 2895 men and 1383 women. 
Their mean age was 36.6 (10.5) years, weight 75.5 (16.4) kg and height 171.6 (9.6) cm. 
 
2.2. Statistical analyses 
We first calculated the numbers of responders defined as 10% through 90% reduction on the BPRS or 
PANSS total score at 4 weeks, with missing data supplemented by the last-observation-carried-forward 
(LOCF) method even if a participant dropped out before the first post-baseline rating. The percentage 
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reduction was calculated according to the formulae: B% = (B0 – B4LOCF) * 100 / (B0 -18) for BPRS and P% 
= (P0 – P4LOCF) * 100 / (P0 – 30) for PANSS, where B0 and P0 are BPRS and PANSS scores at baseline and 
B4LOCF and P4LOCF are respective scores at 4 weeks with LOCF, because 18 and 30 are the minimum 
scores for BPRS and PANSS, respectively, according to the original rating system (Kay et al., 1987; 
Overall and Gorham, 1962). 
We then ran meta-analyses of response rates defined as 10% through 90% reduction for each 
comparison in terms of OR, RR and RD, using Review Manager software by the Cochrane Collaboration 
(2008). Because we are looking for a single index that may remain constant through different 
definitions of response, we used the Mantel-Haenszel fixed effect model (Mantel and Haenszel, 1959). 
However, in order to examine robustness of our findings, we repeated the same analyses based on the 
DerSimonian random effects model (DerSimonian and Laird, 1986). 
Constancy of these three summary indices of treatment effectiveness was examined (i) through visual 
inspection of the obtained indices and their 95% confidence intervals, (ii) I-squared statistics of the 
hypothetical meta-analyses of the relevant trials adopting different thresholds for 10% through 90%, 
and (iii) coefficient of variation (CV). CV is defined as SD/|mean|, and its 95% confidence intervals were 
calculated according to Johnson & Welch (1939). Because heterogeneity may arise from differences in 
baseline severity of the included patients, study year and/or methodologic rigor of the included trials, 
we repeated the analyses by excluding trials that had low baseline BPRS scores (Keefe et al., 2006; 
Lieberman et al., 2003; Tollefson et al., 1997), old trials before year 2000 (Beasley et al., 1997; Beasley 
et al., 1996a; Beasley et al., 1996b; Moller et al., 1997; Puech et al., 1998; Tollefson et al., 1997) or non-
blinded trials (Colonna et al., 2000). 
If any of OR, RR and RD appeared constant through ranges of definitions of response and may therefore 
be given the role of the representative index of effectiveness of one arm over the other regardless of the 
cutoffs in the continuous scale, we then examined if that summary effect measure can accurately predict 
the other effect measures according to the known mathematical relationships among OR, RR and RD on 
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one hand and control event rate (CER; the response rate in the control group) on the other. Given the 
2*2 table as shown in the Introduction, by introducing CER = c/(c+d), we can calculate RR and RD from 
OR using the formulae: 
RR = OR/(1 – CER + CER*OR) 
RD = CER * (RR – 1). 
We can also calculate OR and RD from RR using the same formulae. The degree of absolute agreement 
between the observed values and the predicted values was expressed by way of two-way mixed ANOVA 
intraclass coefficient (ICC) for absolute agreement. 
 
3. RESULTS 
3.1. Visual inspection of the constancy of OR, RR and RD across different definitions of response 
Figures 1, 2 and 3 depict the OR, RR and RD corresponding to the various definitions of response using 
10% through 90% reduction in the BPRS or PANSS total scores for the comparisons olanzapine vs 
haloperidol, amisulpride vs haloperidol and olanzapine vs placebo, respectively. Visual inspection of 
these graphs indicate that both OR and RR appear to remain relatively constant, especially for the 
ranges of 10% through 70% reduction. 
For the extreme ranges of 80% or 90% reduction, there were too few participants to achieve the so-
defined response and the calculated OR and RR were all unstable and resulted in wide 95% confidence 
intervals. 
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3.2. Numerical examination of constancy of OR, RR and RD 
Table 2 lists the I-squared for the hypothetical pooling across all definitions of response, and CV for the 
OR, RR and RD. 
RD produced I-squared statistics which would be interpreted as representing moderate to high 
heterogeneity (Higgins et al., 2003) and were always greater in absolute value than those for RR, which 
were then greater than those for OR, although neither of these differences were statistically significant 
(Wilcoxon signed rank test). Focusing on more homogeneous trials by excluding trials with low baseline 
BPRS scores, old trials or non-blinded trials resulted in very similar I-squared values (Table 2). 
RD also had the greatest CV, while OR had the smallest CV: the differences in CV between RD on one 
hand and OR or RR on the other were both statistically significant, because their 95% CIs did not 
overlap. 
 
3.3. Which relative index of treatment effect enables more accurate prediction of treatment effect on the 
other indices, OR or RR? 
It now appears both OR and RR remain relatively constant through ranges of definitions of response on 
the continuous scale, especially for 10% through 70% where we have non-small control event rates. 
The next question then is which of these can allow more accurate prediction of treatment effect 
according to the other indices, when we apply the mathematical formulae as explained in the Methods 
section. As the observed OR and RR, we took the average of the values for 10% through 70% reduction, 
as these appeared to remain particularly constant in Figures 1 through 3. 
Using this OR and the varying control event rates, the ANOVA ICC (two-way mixed, absolute agreement) 
between the observed and the predicted RRs, RDs and NNTs was 0.94 (0.87 to 0.97), 0.95 (0.90 to 0.98) 
and 0.96 (0.92 to 0.98) respectively for the ranges between 10% through 70%. 
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With regard to the RR, the ANOVA ICC between the observed and the predicted ORs, RDs and NNTs was 
-0.03 (-0.37 to 0.34), 0.61 (0.31 to 0.80) and 0.86 (0.72 to 0.93) respectively. 
 
3.4. Sensitivity analyses 
All the analyses based on random effects model were essentially unchanged. For example, the ANOVA 
ICCs between the RR, RD and NNT predicted from OR and those actually observed were 0.93 (0.85 to 
0.97), 0.95 (0.90 to 0.98) and 0.91 (0.82 to 0.96) respectively for the ranges between 10% through 70%. 
And the corresponding ICCs between the OR, RD and NNT predicted from RR and those actually 
observed were -0.01 (-0.37 to 0.35), 0.59 (0.27 to 0.79) and 0.71 (0.47 to 0.86). Once again, assuming 
constancy of OR enabled excellent prediction of RR, RD and NNT in conjunction with varying control 
event rates, while assuming constancy of RR enabled satisfactory prediction of NNT. 
 
4. DISCUSSION 
Based on individual patient data of 4278 patients with schizophrenia participating in trials of acute 
phase antipsychotic treatment, we examined empirically whether OR, RR or RD remain constant across 
different definitions of response on the BPRS and the PANSS. We found that both OR and RR remain 
relatively constant across plausible ranges of definitions of response and that OR, in particular, was able 
to predict RR, RD and NNT very accurately using mathematical formulae and estimates of the control 
event rate. 
The greater generalizability of relative measures of treatment effectiveness (such as OR and RR) over 
absolute ones (such as RD and NNT) is consistent with previous studies. Using a random subset of 
meta-analyses contained in the Cochrane Library, Furukawa, Guyatt and Griffith (2002) examined the 
concordance between treatment indices of each RCT included in a meta-analysis and the meta-analyzed 
results of all the other RCTs. OR and RR showed the highest concordance rates, even when the control 
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event rate differed substantially, while the concordance for RD was much lower. In other words, OR and 
RR appeared more generalizable than RD, regardless of the control event rate. 
One of the central goals of evidence-based medicine, to individualize group data from clinical research 
to match each individual patient’s values and preferences, seems therefore to have found some 
empirical ground here (Sackett, 2001). By assuming a constant relative index of treatment effectiveness, 
either in terms of OR or RR, and by combining it with each patient’s expected event rate when given the 
control intervention, we can estimate individualized NNT using mathematical formulae as explained in 
the Methods of this paper. In other words, when the relative difference in effect is constant, the absolute 
difference in effect will be different, depending on the expected control event rate that can vary from 
patient to patient. 
The present study has added support that relative indices of treatment may be generalizable even 
across a range of scale-derived definitions of response. In other words, because the relative 
effectiveness is constant across different thresholds, the absolute effectiveness can be calculated taking 
into account the threshold that the patient wishes to achieve. For example, the OR of olanzapine over 
haloperidol to bring about a response in the acute phase treatment of schizophrenia is approximately 
1.5 for various definitions of response of 10% through 70% reductions on the BPRS or PANSS (Cf. 
Figure 1). However, olanzapine causes more significant weight gain than haloperidol, with an NNH 
estimated to be around 6 (95%CI: 4-11) (Duggan et al., 2005). A patient who is normo- to underweight 
now and who does not have any family and other risk factors for obesity may be happy to try 
olanzapine to achieve a 30% or more decrease in disease severity. For this patient, given an estimate 
that approximately 40% of the patients would achieve 30% or more reduction on placebo, NNT will be 
calculated to be 9 and he or she may find this NNT as small as NNH for weight gain to justify treatment 
with olanzapine. On the other hand, another patient who is already somewhat overweight and has 
multiple family history of diabetes mellitus and cardiovascular diseases may like 70% or more decrease 
in the BPRS before he/she selects olanzapine over haloperidol. However, because the control event rate 
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for 70% reduction could be as low as 6% and the corresponding NNT may be as large as 50, he/she 
might reason that trying olanzapine may not be worthwhile. 
Several caveats are in order before we conclude. First, we do not yet know if the current results would 
apply to other continuous outcomes in other areas of psychiatry or medicine. In fact there is no 
mathematical necessity for one measure of effect to be stable across thresholds in all settings, as 
performance of summary effect measures would be dependent on the underlying distribution of the 
continuous outcomes. However, some sporadic examples we find in the literature suggest that the 
present findings may apply in other areas as well. Among patients with active rheumatoid arthritis 
refractory to tumor necrosis factor α, abatacept was superior to placebo in bringing about ACR 20% 
responses with an OR of 4.2 (95%CI: 2.6 to 6.9), ACR 50% responses with an OR of 6.5 (2.5 to 17), and 
ACR 70% responses with an OR of 7.4 (1.7 to 32) (Genovese et al., 2005). For patients with psoriasis, 
ustekinumab, a human interleukin-12/23 monoclonal antibody, beat placebo in reducing the Psoriasis 
Area and Severity Index by at least 50% (OR=45, 95%CI: 26 to 75), by at least 75% (OR=63, 30 to 133) 
and by at least 90% (OR=36, 14 to 89) (Leonardi et al., 2008). Thus in both studies, ORs for different 
thresholds showed largely overlapping confidence intervals that contained all the reported point 
estimates. More definitive analyses would require individual patient data from more studies, and the 
present study was the first to carry out such an examination in the context of second generation 
antipsychotic trials for people with schizophrenia. 
Second, the individual patient data that we had access to did not include important individual patient 
characteristics such as duration of untreated psychosis, years ill, treatment history or concurrent 
psychosocial treatments. How these variables could have moderated the present results is hard to 
predict. However, if the present results are generalizable, we could expect that OR and RR would 
remain relatively constant within each prognostic stratum as defined by such baseline characteristics. 
Third, the included studies are limited to trials around 2000. If the present results would apply to more 
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recent trials, especially in view of the changes in patient selection and given increasing number of failed 
placebo-controlled trials recently, awaits replication. 
Taking all these considerations into account, we think that our results have several important 
implications for research. First, we can safely combine trials that adopted different definitions of 
response in a meta-analysis to derive the pooled OR or RR, which can then be applied to wider ranges of 
response definitions and of patients. Second, in the original report of a clinical trial, however, it will be 
more informative not only to report the OR or RR but also the control event rates for different 
definitions of response (Leucht et al., 2007). Third, when we plan an RCT, given the constant OR, 
mathematics shows that the threshold at which the response rate approaches 50% will provide the 
greatest statistical power. 
The implication of the present study for clinical practices is straightforward. The constant OR across 
different scale-derived definitions of response, in conjunction with varying control event rates, will give 
accurate estimates of individualised NNTs in pharmacotherapy of schizophrenia and possibly in other 
areas of medicine. The RR also remains relatively constant so that it may be used, in conjunction with 
varying control event rates, to estimate NNTs. Using RR has the advantage of allowing busy clinicians 
easier calculation than using OR. 
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Table 1. Characteristics of the included studies 
 
Study Antipsychotic drugs 







Selected patient characteristics 
Möller et al 
1997 (Moller 







Inpatients with paranoid, disorganized or undifferentiated 
schizophrenia (DSM-III-R), BPRS psychotic subscore ≥12 
and at least two BPRS psychosis items ≥4 
Puech et al 








Inpatients with acute exacerbations of paranoid, 
disorganized or undifferentiated schizophrenia (DSM-III-R), 
BPRS psychotic subscore ≥12 and at least two BPRS 
psychosis items ≥4 
Colonna et al 
2000 (Colonna 







In- or outpatients with acute exacerbations of paranoid, 
disorganized or undifferentiated schizophrenia (DSM-III-R), 
at least two BPRS psychosis items ≥4 
Carrière et al 
2000 (Carriere 







Inpatients with paranoid schizophrenia or 
schhizophreniform disorder (DSM-IV) 
Beasley et al 
1997 (Beasley 





6 59.1 Inpatients with acute exacerbations of schizophrenia (DSM-
III-R), BPRS total score ≥ 42, CGI-S ≥ 4 








6 51.5 In- and outpatients with schizophrenia, schizophreniform 
or schizoaffective disorder (DSM-III-R), BPRS total score ≥ 
36 










12 46.8 In- and outpatients with a first episode of schizophrenia, 
schizophreniform or schizoaffective disorder (DSM-IV), at 
least two PANSS psychosis items ≥ 4, CGI-S ≥ 4 
Keefe et al 






8 48.4 In- and outpatients with schizophrenia or schizoaffective 
disorder according to DSM-IV, BPRS total score ≥ 36, at 
least two PANSS psychosis items ≥4 
Beasley et al 
1996 (Beasley 







6 59.9 Inpatients with acute exacerbations of schizophrenia (DSM-
III-R), BPRS total score ≥ 42, CGI-S ≥ 4 
Beasley et al 
1996 (Beasley 





6 55.2 Inpatients with schizophrenia (residual type excluded) 
(DSM-III-R), BPRS total score ≥ 42, CGI-S ≥ 4 
BPRS: Brief Psychiatric Rating Scale, CGI-S: Clinical Global Impression Severity Scale, DSM: Diagnostic and Statistical Manual of Mental Disorders, 
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Table 2. Numerical examination of constancy of OR, RR and RD 
 
 Comparison Scale I-squared CV 











OR olanzapine vs haloperidol BPRS 13% 3% 0% 3% 0.29(0.23 
to 0.38) 
  PANSS 0% 0% 0% 0% 
 amisulpride vs haloperidol BPRS 0% 0% 0% 0% 
 olanzapine vs placebo BPRS 0% 0% 0% 0% 
RR olanzapine vs haloperidol BPRS 43% 11% 0% 43% 0.33 (0.27 
to 0.44) 
  PANSS 11% 13% 0% 11% 
 amisulpride vs haloperidol BPRS 2% 2% 21% 0% 
 olanzapine vs placebo BPRS 0% 0% 0% 0% 
RD olanzapine vs haloperidol BPRS 82% 20% 60% 82% 0.62 (0.55 
to 0.71) 
  PANSS 86% 76% 47% 86% 
 amisulpride vs haloperidol BPRS 43% 43% 58% 35% 
 olanzapine vs placebo BPRS 76% 76% 86% 76% 
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